18F-FDG PET during stereotactic body radiotherapy for stage I lung tumours cannot predict outcome: a pilot study - Wikidata - wikimedia - TriplyDB

18F-FDG PET during stereotactic body radiotherapy for stage I lung tumours cannot predict outcome: a pilot study

18F-FDG PET during stereotactic body radiotherapy for stage I lung tumours cannot predict outcome: a pilot study

http://www.wikidata.org/entity/Q30474874

about

Textural features in pre-treatment [F18]-FDG-PET/CT are correlated with risk of local recurrence and disease-specific survival in early stage NSCLC patients receiving primary stereotactic radiation therapy.Prognositc significance of SUVmax on pretreatment 18 F-FDG PET/CT in early-stage non-small cell lung cancer treated with stereotactic body radiotherapy: A meta-analysis.Positron-emission tomography CT to identify local recurrence in stage I lung cancer patients 1 year after stereotactic body radiation therapy.

P2860

Q35734154-2B8553B9-1ACB-499A-A765-66FC9CA6BBF9 Q38925620-C265B597-E73A-445D-B08F-012A12C337FD Q53112046-2ADAE86D-0919-40DB-844D-6737F9B1516C

P2860

18F-FDG PET during stereotactic body radiotherapy for stage I lung tumours cannot predict outcome: a pilot study

http://www.wikidata.org/entity/Q30474874

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

18F-FDG PET during stereotacti ...... predict outcome: a pilot study

@ast

18F-FDG PET during stereotacti ...... predict outcome: a pilot study

@en

type

label

18F-FDG PET during stereotacti ...... predict outcome: a pilot study

@ast

18F-FDG PET during stereotacti ...... predict outcome: a pilot study

@en

prefLabel

18F-FDG PET during stereotacti ...... predict outcome: a pilot study

@ast

18F-FDG PET during stereotacti ...... predict outcome: a pilot study

@en

P1433

Q30474874-A1D72B84-6EEE-4C81-B56E-47B3A515063F

P1476

Q30474874-EFCF7FEC-8D33-4CD0-9586-2CAA46FAB90D

P2093

Q30474874-2567B43E-FFA5-483C-8F54-23DA5900568E

Q30474874-933FBA74-817C-4B61-970F-5DA83217BA29

Q30474874-A8224E00-3E53-4387-BA07-D44EC52B4A7E

Q30474874-BF45503C-596F-49DB-B30C-C6255D784843

Q30474874-F992D820-3E84-49E0-923E-76B7B2D8AD37

P2860

Q30474874-41DACBBD-2BF9-413D-8875-02D6403B0D07

Q30474874-6A12C215-0901-49C3-A5CB-93ED1068A37F

Q30474874-7BA3EF61-8075-42D9-BF42-17108C985CF0

Q30474874-860330ED-4E90-4590-81B3-57DCF91A1F97

Q30474874-865EE1B8-034F-4E82-9575-8D6020CF98D4

Q30474874-89536D69-1E77-45AD-A651-EF10BF4EBBCA

Q30474874-8AD254F0-930B-48C0-99CA-4247312D6C38

Q30474874-96EDA417-87A3-4623-AB23-AA4C954BDA26

Q30474874-AE4D0EB2-1FEF-4A67-AE69-96E1873DAB6C

Q30474874-B34728DA-1FA2-48CF-AEEA-7FCDBB216942

P2888

Q30474874-31A19246-BF23-44F9-8A33-33056558F224

P304

Q30474874-7FACCBD3-6D6E-4CFA-90F9-75D1E2B4E02E

P31

Q30474874-68B6196E-A714-478D-9A42-543A019E3761

P356

Q30474874-FE9078BE-BEF9-42EE-8A1F-3AC6C6DA1E3E

P433

Q30474874-1BA74CCD-9889-43FC-B7C3-6C257174C31B

P478

Q30474874-D6F0E26E-C6ED-4CE4-BD5F-A31E8A80A132

P50

Q30474874-1DBFFA42-8106-42B8-A6DD-06C45AF7AFA1

P577

Q30474874-3FFC132C-C001-4CBF-BFAB-5B1687E73D69

P5875

Q30474874-C1601832-9910-4260-8EDE-0B232C54A5B4

P698

Q30474874-B95B893B-B421-4713-BB82-B551C385F9EA

P932

Q30474874-29ECFF57-A3EB-4109-BAAE-5F697FAE681F

P356

S00259-010-1706-8

P1433

European Journal of Nuclear Medicine and Molecular Imaging

P1476

18F-FDG PET during stereotacti ...... predict outcome: a pilot study

@en

P2093

Erwin M Wiegman

http://www.w3.org/2001/XMLSchema#string

Harry J M Groen

http://www.w3.org/2001/XMLSchema#string

Jan F Ubbels

http://www.w3.org/2001/XMLSchema#string

Jan Pruim

http://www.w3.org/2001/XMLSchema#string

Johannes A Langendijk

http://www.w3.org/2001/XMLSchema#string

P2860

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

A pilot trial of serial 18F-fluorodeoxyglucose positron emission tomography in patients with medically inoperable stage I non-small-cell lung cancer treated with hypofractionated stereotactic body radiotherapy

Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group.

Evidence-based medicine in the treatment of non-small-cell lung cancer.

Potential clinical utility of dual time point FDG-PET for distinguishing benign from malignant lesions: implications for oncological imaging.

Systemic review of the patterns of failure following stereotactic body radiation therapy in early-stage non-small-cell lung cancer: clinical implications.

Evaluation of D-18F-FMT, 18F-FDG, L-11C-MET, and 18F-FLT for monitoring the response of tumors to radiotherapy in mice.

Recommendations for implementing stereotactic radiotherapy in peripheral stage IA non-small cell lung cancer: report from the Quality Assurance Working Party of the randomised phase III ROSEL study.

FDG-PET and stereotactic body radiotherapy (SBRT) for stage I non-small-cell lung cancer.

Dual-time point 18F-FDG PET/CT scan for differentiation between 18F-FDG-avid non-small cell lung cancer and benign lesions.

P2888

s00259-010-1706-8

P304

1059-1063

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00259-010-1706-8

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

38

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-01-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49732519

http://www.w3.org/2001/XMLSchema#string

P698

21210108

http://www.w3.org/2001/XMLSchema#string

P932

3094529

http://www.w3.org/2001/XMLSchema#string